Founded in 2019, JLS Fund is a unique venture capital fund focused primarily on neuroscience, mental health and enabling tools and infrastructure. From Pre-seed and Seed investing to Series A and later-stage secondaries transitioning to buyout.
Mental health company dedicated to providing access to safe and affordable psychedelic-assisted therapy, beginning with ketamine therapy.
A clinical-stage neuroscience biotech transforming the treatment paradigm of psychiatric diseases.
A life science company focused on mushroom derived medicines.
MindMed discovers and develops psychedelics inspired medicine.
Biotechnology company developing psychedelic entities for treating addiction.
Reimagines psychoactive natural products as the building blocks for the next generation of neurological products
Light Alliance Summit: Cuba 2026 - An Immersive Journey into Conscious Community & Collective Impact
March 19-22, 2026
Simeon will be speaking at the second annual Light Alliance Summit—an inspiring gathering of global visionaries, conscious leaders, entrepreneurs, investors, and creators committed to co-creating a future defined by abundance, wellness, and meaningful connection.
EpilepsyGTx raises $33 million. And could this epilepsy treatment generate $4 billion in sales?
Check Out Our Substack!
.png){kind=small}
